Company profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Source: Cofisem - Last Update: 01 Aug 2019
Key Executives
Chief Executive Officer Jean-Christophe Tellier
Chief Financial Officer Detlef Thielgen
VP, Communication France Nivelle
Investor Relations Antje Witte
Source: Cofisem - Last Update: 01 Aug 2019
Key figures
Millenium 2018 2017 2016 2015 2014
Net sales 4,632,000 4,530,000 4,178,000 3,876,000 3,344,000
Income from ordinary activities 4,632,000 4,530,000 4,178,000 3,876,000 3,344,000
Operating income 1,109,000 1,087,000 876,000 522,000 273,000
Cost (net) of financial indebtedness -46,000 -42,000 -54,000 -79,000 -94,000
Equity-accounted companies' contribution to results -1,000
Net profit from discontinued activities 8,000 1,000 -23,000 359,000 94,000
Net income 823,000 771,000 542,000 674,000 199,000
Net income (Group share) 800,000 753,000 520,000 623,000 209,000
Fiscal year end 12.18 12.17 12.16 12.15 12.14
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 01 Aug 2019
Shareholder information
Free float 51.76 %
Financière de Tubize 35.00 %
Blackrock Inc 5.21 %
Vanguard Health Care Fund 5.01 %
Group-owned stock 3.02 %
Source: Cofisem - Last Update: 23 Apr 2019

Address

UCB

Allée de la Recherche 60
BE-1070 Bruxelles, Bruxelles-Capitale
Belgium
Source: Cofisem - Last Update: 01 Aug 2019

Contact

Antje Witte
Phone number: +32 (2) 559 9414
Source: Cofisem - Last Update: 01 Aug 2019